Cargando…

ALK mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutations

The ALK gene is a major oncogene of neuroblastoma cases exhibiting ALK activating mutations. Here, we characterized two neuroblastoma cell lines established from a stage 4 patient at diagnosis either from the primary tumor (PT) or from the bone marrow (BM). Both cell lines exhibited similar genomic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Durand, Simon, Pierre-Eugène, Cécile, Mirabeau, Olivier, Louis-Brennetot, Caroline, Combaret, Valérie, Colmet-Daage, Léo, Blanchard, Orphée, Bellini, Angela, Daudigeos-Dubus, Estelle, Raynal, Virginie, Schleiermacher, Gudrun, Baulande, Sylvain, Delattre, Olivier, Janoueix-Lerosey, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697636/ https://www.ncbi.nlm.nih.gov/pubmed/31452835 http://dx.doi.org/10.18632/oncotarget.27119

Ejemplares similares

Activated ALK signals through the ERK–ETV5–RET pathway to drive neuroblastoma oncogenesis
por: Lopez-Delisle, Lucille, et al.
Publicado: (2018)

Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma
por: Cazes, Alex, et al.
Publicado: (2014)

QuantumClone: clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction
por: Deveau, Paul, et al.
Publicado: (2018)

Study of chromatin remodeling genes implicates SMARCA4 as a putative player in oncogenesis in neuroblastoma
por: Bellini, Angela, et al.
Publicado: (2019)

Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cells
por: Montavon, Gisèle, et al.
Publicado: (2014)

Hyperactivation of Alk induces neonatal lethality in knock-in Alk(F1178L) mice
por: Lopez-Delisle, Lucille, et al.
Publicado: (2014)

High CD44 expression is not a prognosis marker in patients with high-risk neuroblastoma
por: Louis-Brennetot, Caroline, et al.
Publicado: (2020)

BET and CDK Inhibition Reveal Differences in the Proliferation Control of Sympathetic Ganglion Neuroblasts and Adrenal Chromaffin Cells
por: Sriha, Jessica, et al.
Publicado: (2022)

Breakpoint Features of Genomic Rearrangements in Neuroblastoma with Unbalanced Translocations and Chromothripsis
por: Boeva, Valentina, et al.
Publicado: (2013)

Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse
por: Chen, Lindi, et al.
Publicado: (2016)

Detection of tumor ALK status in neuroblastoma patients using peripheral blood
por: Combaret, Valérie, et al.
Publicado: (2015)

Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastoma
por: Costa, Ana, et al.
Publicado: (2022)

Internalization and Down-Regulation of the ALK Receptor in Neuroblastoma Cell Lines upon Monoclonal Antibodies Treatment
por: Mazot, Pierre, et al.
Publicado: (2012)

Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
por: Tucker, Elizabeth R., et al.
Publicado: (2023)

Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data
por: Boeva, Valentina, et al.
Publicado: (2012)

Learning smoothing models of copy number profiles using breakpoint annotations
por: Hocking, Toby Dylan, et al.
Publicado: (2013)

Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)
por: Bellini, Angela, et al.
Publicado: (2021)

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation
por: Borenäs, Marcus, et al.
Publicado: (2021)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition
por: Urbanska, Edyta M., et al.
Publicado: (2020)

Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels
por: Duijkers, Floor A. M., et al.
Publicado: (2011)

Plasticity in Neuroblastoma Cell Identity Defines a Noradrenergic-to-Mesenchymal Transition (NMT)
por: Gautier, Margot, et al.
Publicado: (2021)

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib
por: Guan, Jikui, et al.
Publicado: (2018)

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance
por: Okada, Koutaroh, et al.
Publicado: (2019)

MYCN and mutationally activated ALK synergise in neuroblastoma
Publicado: (2012)

Loss of ALK hotspot mutations in relapsed neuroblastoma
por: Allinson, Lisa M., et al.
Publicado: (2022)

Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma
por: Zdzalik, Daria, et al.
Publicado: (2014)

Reversible transitions between noradrenergic and mesenchymal tumor identities define cell plasticity in neuroblastoma
por: Thirant, Cécile, et al.
Publicado: (2023)

Short progression‐free survival of ALK inhibitors sensitive to secondary mutations in ALK‐positive NSCLC patients
por: Haratake, Naoki, et al.
Publicado: (2019)

Clinical Characteristics and Outcome of Patients with Neuroblastoma Presenting Genomic Amplification of Loci Other than MYCN
por: Guimier, Anne, et al.
Publicado: (2014)

SegAnnDB: interactive Web-based genomic segmentation
por: Hocking, Toby D., et al.
Publicado: (2014)

Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation
por: Ogata, Misato, et al.
Publicado: (2018)

Identification of ALK Mutation in Neuroblastoma on the Point of Molecular Heterogeneity
por: Aktaş, Tekincan Çağrı, et al.
Publicado: (2023)

Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells
por: Berlak, Mareike, et al.
Publicado: (2022)

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
por: Damm-Welk, Christine, et al.
Publicado: (2016)

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
por: Zhang, Xuchao, et al.
Publicado: (2010)

Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment
por: Javanmardi, Niloufar, et al.
Publicado: (2019)

TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations
por: Murray, Brion W., et al.
Publicado: (2021)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
por: Du, Xue, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qcurodij1t4a82joke68in86s9